| case | gender | age | duration of suffering | concomitant drugs | PIH(IGIR) | PIE(IGIR) | number of inflammatory lesions | number of comedo | adverse reactions | ||
| 0 w | 12 w | 0 w | 12 w | ||||||||
| 1 | F | 42 | 27 | BPO/ADA | marked | moderate | 6 | 0 | 9 | 2 | none |
| 2 | F | 25 | 13 | BPO/ADA | moderate | mild | 15 | 20 | 33 | 30 | none |
| 3 | M | 22 | 8 | Seijobofuto, heparinoid, BPO/ADA | moderate | excellent | 2 | 0 | 14 | 14 | none |
| 4 | F | 15 | 5 | heparinoid, BPO/ADA | marked | complete | 18 | 3 | 20 | 8 | none |
| 5 | F | 39 | 19 | BPO/ADA | worse | moderate | 5 | 1 | 12 | 12 | none |
| 6 | F | 24 | unknown | BPO/ADA | excellent | mild | 24 | 5 | 40 | 13 | none |
| 7 | F | 47 | 34 | BPO | mild | complete | 2 | 0 | 5 | 4 | none |
| 8 | F | 40 | unknown | heparinoid, BPO/ADA | mild | marked | 5 | 0 | 7 | 2 | none |